Table 1 Patient characteristics
From: Cerebrospinal fluid penetration of fosfomycin in patients with ventriculitis: an observational study
Age [years] | 57 ± 12 |
Gender | Male: 59% |
Female: 41% | |
Body height [cm] | 175 ± 7 |
Weight [kg] | 84 ± 20 |
BMI [kg/m2] | 27 ± 5 |
Creatinine [mg/dL] | 0.64 ± 0.36 |
eGFR CKD-EPI [ml/min/1.73m2] | 110 ± 32 |
Serum sodium [mmol/L] | 142 ± 8 |
GOS | GOS 1: 2 (12%) |
GOS 2: 1 (6%) | |
GOS 3: 11 (65%) | |
GOS 4: 0 (0%) | |
GOS 5: 3 (17%) | |
Underlying disease | Aneurysmal subarachnoid hemorrhage: 8 (47%) |
Neoplasia: 4 (23%) | |
Intracerebral hemorrhage: 3 (18%) | |
Ventricular-peritoneal shunt infection: 2 (12%) | |
LOS [days] | 25 [21–52] |
Inflammation markers on day 1 of fosfomycin treatment | |
CSF glucose [mg/dL] | 530 [442–650] |
CSF cell count [× 106/L] | 582 [162–2562] |
CSF protein level [mg/dL] | 1163 [802- 2393] |
CSF lactate [mmol/L] | 5 ± 2 |
CSF IL-6 [pg/mL] | 1782 [61–13229] |
SAPS II | 36 [29–60] |
White blood count in serum [x 109/L] | 9.4 ± 5.4 |
C-reactive protein [mg/L] | 67 [27–99] |